-

Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient

Recognizing superior service, support, reliability, ethics and integrity

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi has been named the 2022 Pharmaceutical Supplier Partner of the Year by Vizient, Inc., the nation’s largest member-driven health care performance improvement company. The recognition was September 19-21 at the 2022 Vizient Connections Summit in Las Vegas.

The Pharmaceutical Supplier Partner of the Year award recognizes suppliers for their superior service, support, reliability, ethics and integrity. This year, Vizient recognized Fresenius Kabi for providing comprehensive contract access and proactively engaging the broader Vizient enterprise, including consulting and Pharmacy Networks, in support of Vizient pharmacy members.

“We are honored to receive the 2022 Pharmaceutical Supplier Partner of the Year award from Vizient. Customer focus is one of our company values and everyone at Fresenius Kabi plays a critical role in supporting Vizient, its members and the patients they serve. This recognition is a testament to the dedication and care our employees demonstrate, regardless of their individual roles,” said Scott Meacham, president, Pharmaceuticals at Fresenius Kabi USA.

Since 2016, Fresenius Kabi has been named the Vizient Pharmaceutical Supplier Partner of the Year three times, received the overall Supplier of the Year award, and was recognized twice as the Vizient Strategic Programs Pharmaceutical Supplier of the Year.

“We are pleased to recognize Fresenius Kabi as this year’s winner of the Pharmaceutical Supplier Partner of the Year award. Their commitment to product quality and to delivering the highest level of service to our members is exemplary. It is evident that the needs of hospitals and patients are at the center of their market strategy,” said Bharat Sundaram, president and chief operating officer for Vizient.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at http://www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.

Contacts

Joanie Clougherty (614) 717-5741
joan.clougherty@fresenius-kabi.com

Fresenius Kabi


Release Versions

Contacts

Joanie Clougherty (614) 717-5741
joan.clougherty@fresenius-kabi.com

Social Media Profiles
More News From Fresenius Kabi

Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has been certified by the Top Employers Institute as a 2026 Top Employer in the United States and North America. This affirms the company’s ongoing commitment to creating a positive work environment. Globally, Fresenius Kabi was certified as a Top Employer for 2026 in 13 countries and two regions. Since 2023, Fre...

Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under which Fresenius Kabi has an exclusive license to develop, manufacture, and distribute products that incorporate TQ Therapeutics’ proprietary cell selection technology. The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing. Frese...

Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara®

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi® (ustekinumab-aauz) in a 45 mg/0.5 mL single-dose vial for subcutaneous injection. Otulfi® is a prescription medicine and the brand name for Fresenius Kabi’s FDA-approved biosimilar of the reference product, Stelara® (ustekinumab). With this addition, Fresenius Kabi now offers...
Back to Newsroom